Sugi Predict

Sugi Predict / Compounds / SCHEMBL2949180

SCHEMBL2949180

SCHEMBL2949180

O=C(O)COc1ccc(F)cc1F

nearest known ligand 0.70

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ PKM P14618 1/20 0.70
▸ PTGDR2 Q9Y5Y4 5/20 0.59
▸ FFAR1 O14842 6/20 0.52
▸ PPARD Q03181 2/20 0.52
▸ PPARG P37231 1/20 0.52
▸ TDP1 Q9NUW8 1/20 0.50
▸ AKR1A1 P14550 1/20 0.49
▸ AKR1B1 P15121 1/20 0.49
▸ PTGDR Q13258 1/20 0.49
▸ POLB P06746 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.49
▸ GLA P06280 1/20 0.49
▸ L3MBTL1 Q9Y468 1/20 0.49
▸ PTGER2 P43116 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18045699 0.87 PKM (0.72) PKMPTGDR2FFAR1TDP1PTGDR
SCHEMBL3949993 0.84 PKM (0.50) PKMPTGDR2POLBSMN1; SMN2
SCHEMBL1332096 0.84 PKM (0.68) PKMPTGDR2TDP1PTGDRPOLB
SCHEMBL3203774 0.82 PTGDR2 (0.64) PKMPTGDR2TDP1AKR1A1AKR1B1
SCHEMBL3727991 0.82 TDP1 (0.70) PKMPTGDR2TDP1PTGDRSMN1; SMN2
SCHEMBL4138843 0.82 PKM (0.71) PKMPTGDR2TDP1AKR1A1AKR1B1
SCHEMBL4626659 0.82 PKM (0.66) PKMPTGDR2TDP1PTGDRPOLB
SCHEMBL19555393 0.82 TDP1 (0.70) PTGDR2FFAR1PPARDPPARGTDP1
SCHEMBL9912420 0.82 FFAR1 (0.61) PKMPTGDR2FFAR1PPARDPPARG
SCHEMBL2112042 0.82 PKM (1.00) PKMPTGDR2TDP1PTGDRPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3848464-A1 METHOD FOR SITE-SPECIFIC MUTAGENESIS OF MEDICAGO SATIVA GENE BY USING CRISPR/CAS9 SYSTEM Guangdong Sanjie Forage Biotechnology Co., Ltd (CN) 2021-07-14 — — EP claimed
WO-2020007331-A1 METHOD FOR SITE-SPECIFIC MUTAGENESIS OF MEDICAGO SATIVA GENE BY USING CRISPR/CAS9 SYSTEM 广东三杰牧草生物科技有限公司 2020-01-09 — — WO claimed
US-7015247-B2 Ibuprofen-aspirin, hydroxymethylacylfulvene analogs and L-sugar illudin analogs GUTTAG ALVIN 2006-03-21 — — US claimed
US-20030008833-A1 Ibuprofen-aspirin, hydroxymethylacylfulvene analogs and L-sugar illudin analogs GUTTAG ALVIN (US) 2003-01-09 — — US claimed
US-20020065254-A1 Ibuprofen-aspirin and hydroxymethylacylfulvene analogs GUTTAG ALVIN (US) 2002-05-30 — — US claimed
EP-3704094-B1 MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES LLC (US) 2026-03-11 — — EP disclosed
US-20250388604-A1 Compounds and Their Use as PDE4 Activators MIRONID LIMITED (GB) 2025-12-25 — — US disclosed
EP-4572762-A1 COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS Mironid Limited (GB) 2025-06-25 — — EP disclosed
US-20250122188-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES LLC (US) 2025-04-17 — — US disclosed
WO-2025072539-A1 AMINO ACID COMPOUNDS WITH NITROGEN LINKERS AND USES THEREOF PLIANT THERAPEUTICS, INC. (US) 2025-04-03 — — WO disclosed
US-12139478-B2 Compounds, compositions and methods DENALI THERAPEUTICS INC. (US) 2024-11-12 — — US disclosed
US-20240166652-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ABBVIE INC. 2024-05-23 — — US disclosed
EP-1678123-A1 TETRAHYDRO-NAPHTHALENE AND UREA DERIVATIVES Bayer HealthCare AG (DE) 2006-07-12 — — EP disclosed
US-7015247-B2 Ibuprofen-aspirin, hydroxymethylacylfulvene analogs and L-sugar illudin analogs GUTTAG ALVIN 2006-03-21 — — US disclosed
US-20050107408-A1 Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones ROCHE PALO ALTO LLC 2005-05-19 — — US disclosed
WO-2005040100-A1 TETRAHYDRO-NAPHTHALENE AND UREA DERIVATIVES BAYER HEALTHCARE AG (DE) 2005-05-06 — — WO disclosed
US-20030008833-A1 Ibuprofen-aspirin, hydroxymethylacylfulvene analogs and L-sugar illudin analogs GUTTAG ALVIN (US) 2003-01-09 — — US disclosed
US-6436916-B1 PHENOLIC ESTERS OF IBUPROFEN WITH SALICYLIC ACID OR ITS NONTOXIC SALTS USED AS ANTITUMOR AGENT GUTTAG ALVIN (US) 2002-08-20 — — US disclosed
US-20020065254-A1 Ibuprofen-aspirin and hydroxymethylacylfulvene analogs GUTTAG ALVIN (US) 2002-05-30 — — US disclosed
EP-0623605-A2 Substituted piperazines as antiretroviral medicaments BAYER AG (DE) 1994-11-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250122188-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ATF4, ATF1, DDIT3 PKM 575/4885PTGDR2 1727/4885FFAR1 1632/4885
US-12139478-B2 Compounds, compositions and methods EIF4EBP1, EIF4B, EIF4E PKM 2229/4885PTGDR2 2448/4885FFAR1 4047/4885
US-20240166652-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ATF4, ATF1, DDIT3 PKM 575/4885PTGDR2 1727/4885FFAR1 1632/4885
US-20250388604-A1 Compounds and Their Use as PDE4 Activators PDE4A, PDE7A, PDE4B PKM 740/4885PTGDR2 348/4885FFAR1 1340/4885
US-20050107408-A1 Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones MAPK1, MAPK7, MAPK6 PKM 1109/4885PTGDR2 235/4885FFAR1 529/4885
US-20020065254-A1 Ibuprofen-aspirin and hydroxymethylacylfulvene analogs PTGES3, HPGDS, PTGES PKM 4303/4885PTGDR2 45/4885FFAR1 2172/4885
US-20030008833-A1 Ibuprofen-aspirin, hydroxymethylacylfulvene analogs and L-sugar illudin analogs GALE, TPT1, HPSE PKM 4602/4885PTGDR2 1291/4885FFAR1 2403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.